COVID-19 convalescent plasma showed a likely benefit for patients early in the pandemic before remdesivir and corticosteroids were in use, according to results of a landmark study published today inJAMA Internal Medicinethat included physician-scientists at The University of Texas Health Science Center at Houston (UTHealth Houston).

UTHealth Houston and The University of Texas Health Science Center at Tyler participated in the National Institutes of Health-funded randomized clinical trial as part of the Center for Clinical and Translational Sciences (CCTS). Called CONTAIN COVID-19, the clinical trial was established by New York University (NYU) and Montefiore Medical Center/Albert Einstein College of Medicine to evaluate the safety and efficacy of convalescent plasma in hospitalized coronavirus patients. UTHealth Houston carried out this study locally in partnership with Memorial Hermann and Harris Health’s Lyndon B. Johnson Hospital, enrolling underserved populations throughout Harris County.

试验表明，康复血浆是安全且耐受性良好的。在大流行的早期，血浆具有较高的抗体水平，尤其是在免疫抑制人群中，它的效果最佳。

“这项具有里程碑意义的研究一劳永逸地表明，在没有其他疗法的情况下，在大流行中，康复血浆是一个重要的对策。这是一个重要的发现，奠定了对未来大流行的快速反应的基础。”Luis Ostrosky, MD, professor and director of the Division of Infectious Diseases at McGovern Medical School at UTHealth Houston. “This trial, the largest of its kind, also showed that with proper funding and structure, researchers across the country were able to come together quickly in the middle of a global crisis to explore this therapeutic intervention.”

Results of the trial also showed that after the introduction of remdesivir and corticosteroids, efficacy dropped and by the end of the 11-month trial, there was no difference in outcome between plasma and placebo in patients at 14 and 28 days. However, patients on corticosteroids, but not remdesivir, appeared to benefit from convalescent plasma at day 14.

因为病人的性格cteristics, available treatments, and the virus, changed over time, subgroup analyses were done, which revealed the possible benefit for patients in the first quarter of the trial, a period from April to June 2020.

Participants in that first quarter were older, less severely ill, had a longer duration of symptoms, and received high-titer plasma. A shorter duration of symptoms is an indication of a more severe case of the viral infection.

“Convalescent plasma could be an important early treatment tool in places that don’t have access to monoclonal antibodies, corticosteroids, remdesivir, or other therapies,” saidBela Patel, MD, co-investigator, professor and director of the Division of Critical Care, and Graham Distinguished University Chair at McGovern Medical School. “It should also be considered for patients who are immunosuppressed and those whose B cell function is compromised.”

Researchers also reported that, in addition to the introduction of corticosteroids and remdesivir, the decrease in efficacy over time may have been due to using convalescent plasma that originated from New York City before other viral variants emerged.

“It is vitally important to do research such as this during a pivotal public health crisis to determine what works and what doesn’t and use that information for future pandemics. We are proud to be part of such a milestone clinical trial,” saidDavid McPherson，医学博士，审判的共同研究人员，CCTS的首席研究员，Uthealth Houston McGovern医学院内科部门主席以及James T.和Nancy B. Willerson主席。

The trial was in funded in past with an $8 million grant (3UL1TR003167-02S1) from the National Center for Advancing Translational Sciences, part of the National Institutes of Health.

Media Inquiries: 713-500-3030